Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.63 |
| ▸ | DRD3 | P35462 | 4/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.49 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057678 | 0.83 | DRD2 (0.62) | DRD2HTR2CKCNH2 | |
| SCHEMBL23102128 | 0.83 | KCNH2 (0.54) | DRD2DRD3PROKR1KDM2BKCNH2 | |
| SCHEMBL15650089 | 0.82 | DRD2 (0.55) | DRD2DRD3HTR2CPROKR1KCNH2 | |
| SCHEMBL10351689 | 0.82 | DRD2 (0.55) | DRD2DRD3ACHE | |
| SCHEMBL7352591 | 0.82 | DRD2 (0.71) | DRD2DRD3HTR2CPROKR1KCNH2 | |
| SCHEMBL13416032 | 0.82 | DRD2 (0.71) | DRD2DRD3HTR2CPROKR1KCNH2 | |
| SCHEMBL7323009 | 0.81 | DRD3 (0.66) | DRD2DRD3 | |
| SCHEMBL8437990 | 0.80 | DRD2 (0.81) | DRD2DRD3KCNH2 | |
| SCHEMBL7353465 | 0.80 | DRD2 (0.81) | DRD2DRD3KCNH2 | |
| SCHEMBL11628506 | 0.80 | DRD2 (0.54) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | DRD2 2954/4885DRD3 2908/4885HTR2C 4577/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | DRD2 3081/4885DRD3 3059/4885HTR2C 4504/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | DRD2 2649/4885DRD3 2575/4885HTR2C 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.